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Nuclear receptor 2E1 (NR2E1) is expressed in human fetal
and adult brains; however, its role in human brain–
behavior development is unknown. Previously, we have
corrected the cortical hypoplasia and behavioral abnor-
malities in Nr2e1
2/2 mice using a genomic clone span-
ning human NR2E1, which bolsters the hypothesis that
NR2E1 may similarly play a role in human cortical and
behavioral development. To test the hypothesis that
humans with abnormal brain–behavior development
may have null or hypomorphic NR2E1 mutations, we
undertook the first candidate mutation screen of NR2E1
by sequencing its entire coding region, untranslated,
splice site, proximal promoter and evolutionarily con-
served non-coding regions in 56 unrelated patients with
cortical disorders, namely microcephaly. We then geno-
typed the candidate mutations in 325 unrelated control
subjects and 15 relatives. We did not detect any coding
region changes in NR2E1; however, we identified seven
novel candidate regulatory mutations that were absent
from control subjects. We used in silico tools to predict
the effects of these candidate mutations on neural
transcription factor binding sites (TFBS). Four candidate
mutations were predicted to alter TFBS. To facilitate the
present and future studies of NR2E1, we also elucidated
its molecular evolution, genetic diversity, haplotype
structure and linkage disequilibrium by sequencing an
additional 94 unaffected humans representing Africa, the
Americas, Asia, Europe, the Middle East and Oceania, as
well as great apes and monkeys. We detected strong
purifying selection, low genetic diversity, 21 novel poly-
morphisms and five common haplotypes at NR2E1.W e
conclude that protein-coding changes in NR2E1 do not
contribute to cortical and behavioral abnormalities in the
patients examined here, but that regulatory mutations
may play a role.
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Genes with expression patterns and developmental functions
consistent with a role in regulating neurogenesis and cortical
size are suitable for studying the genetic basis of human brain
development and evolution (Gilbert et al. 2005; Kornack &
Rakic 1998; Rakic 1995). To date, only a limited number of
genes have been identified that are expressed at sites of
cortical neurogenesis that are known to regulate neural stem
cells, forebrain size and behavior. One such gene is the
nuclear receptor 2E1 (Nr2e1; previously Mtll, Tailless, Tll
and Tlx), for which a clear role in mouse brain–behavior
development makes it an excellent candidate for genetic
studies of human abnormal brain–behavior development and
evolution.
NR2E1 is expressed in human fetal brain (Strausberg et al.
2002) and in mouse embryonic forebrain (Monaghan et al.
1995) and is also detected in the adult forebrains of humans
and mice (Jackson et al. 1998; Shi et al. 2004). Nr2e1 is
required for normal temporal regulation of cortical neurogene-
sis during embryonic development and regulates proliferation
and differentiation of neural progenitor cells in the embryonic
and adult mouse cortex (Roy et al. 2002, 2004; Shi et al. 2004).
Micedeleted for both copies ofNr2e1 (Nr2e1
 / ) show cortical
hypoplasia, limbic system abnormalities, cognitive impairment,
short stature, vision problems and abnormal social behaviors
that include pathological violence (Christie et al. 2006; Kumar
et al. 2004b; Land & Monaghan 2003; Miyawaki et al. 2004;
Roy et al. 2002; Young et al. 2002).
Multiple additional lines of evidence support a role for
NR2E1 in human brain development. First, we have recently
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doi: 10.1111/j.1601-183X.2006.00277.x 503corrected the cortical and behavioral abnormalities of Nr2e1
 / 
mice using a genomic clone spanning the human NR2E1
locus (Abrahams et al. 2005), providing robust evidence that
human and mouse NR2E1 are functionally equivalent in mice.
Second, members of the nuclear receptor superfamily have
been implicated in disorders of human brain and behavior,
including NR4A2 (Buervenich et al. 2000; Chen et al. 2001;
Hering et al. 2004; Iwayama-Shigeno et al. 2003; Le et al.
2003; Smith et al. 2005) and the estrogen receptor (Westberg
et al. 2003). Importantly, mutations in human and mouse
NR2E3, a gene closely related to NR2E1, produce similar eye
developmental abnormalities (Akhmedov et al. 2000; Haider
et al. 2000), suggesting that human and mouse NR2E1
mutations might also cause the same phenotype. Third, some
individuals with cortical abnormalities have de novo interstitial
deletions encompassing the NR2E1 locus at 6q21. Chery
et al. (1989) report a de novo interstitial deletion of 6q21 in a
male with moderate microcephaly, facial dysmorphism and
psychomotor retardation (Chery et al. 1989). In addition,
patient 2 reported by Hopkin et al. (1997) has an interstitial
deletion that includes 6q21 and presents with severe intra-
uterine growth retardation and severe congenital microceph-
aly (Hopkin et al. 1997).
NR2E1 hypomorphic mutations could underlie human
cortical malformations. Mice deleted for a single copy of
Nr2e1 (Nr2e1
þ/ ) show premature neurogenesis during early
corticogenesis that results in reduced neuron numbers that
are intermediate to that produced in Nr2e1
þ/þ and Nr2e1
 / 
mice (Roy et al. 2004), providing strong support for dosage
sensitivity for Nr2e1 during cortical development. Support for
a hypomorphic mechanism is also provided by studies in mice
that are double heterozygotes for Nr2e1 and Pax6, which
result in altered regionalization of the cerebral cortex (Stenman
et al. 2003). Mice heterozygous for either Nr2e1 or Pax6
alone do not show alterations in cortical gene expression at
the pallial–subpallial boundary, indicating that normal cortical
regionalization at this boundary involve a genetic interaction
between Pax6 and Nr2e1 (Stenman et al. 2003). Importantly,
human cortical malformations are known to result from PAX6
haploinsufficiency (Sisodiya et al. 2001). In addition, Glaser
et al. (1994) describe a newborn boy with homozygous muta-
tions of PAX6 that results in severe congenital microcephaly
and polymicrogyria (Glaser et al. 1994). Taken together,
mouse and human genetic studies support the proposal that
some human cortical disorders may involve a single- or
a multigene mechanism involving NR2E1 null or hypomorphic
mutations.
In this study, we report the first genetic analyses of NR2E1
in patients. To test the hypothesis that humans with abnormal
cortical development and mental retardation may have null or
hypomorphic mutations in NR2E1, we searched for candidate
mutations by sequencing the complete coding region, 50- and
30-untranslated (UTR), splice site, proximal promoter and
evolutionarily conserved non-coding regions in 56 unrelated
patients with unexplained congenital microcephaly, a neuro-
developmental disorder characterized by marked reduction in
cortical size that may result from failure of neurogenesis
(Dobyns 2002; Mochida & Walsh 2001). We genotyped
candidate mutations in ethnically matched control subjects
that included 137 Africans and 188 Europeans. To guide the
present and future studies of NR2E1, we also elucidated its
molecular evolution, genetic diversity, haplotype structure
and linkage disequilibrium by sequencing an additional 94
unaffected humans representing Africa, the Americas, Asia,
Europe, the Middle East and Oceania, as well as chimpanzee,
gorilla, orangutan and macaque.
Materials and methods
Human and non-human primate samples
Approval for this study was obtained from The University of British
Columbia (Certificate of Approval # C99-0524), Child & Family
Research Institute of British Columbia (Certificate of Approval #
W00-0005) and the Department of Medical Genetics (Certificate of
Approval #6-3-20). The research followed the Canada’s Tri-Council
Statement on ‘Ethical Conduct for Research Involving Humans’
(sections 2.5–2.7). We studied 56 unrelated patients with congenital
microcephaly (with or without simplified gyral patterns) and additional
features resembling Nr2e1
 /  mice, including short stature, vision
problems, cognitive impairment and abnormal social behaviors.
Patient demographic and clinical data are reported in Table 1. For
a subset of patients, unaffected and affected family members that
included 14 parents and four siblings were also studied. The following
control subjects without severe cortical malformations or known
behavioral problems were studied: (1) 110 individuals of African
descent obtained from the Coriell Cell Repository (http://coriell.umdnj.
edu/); (2) 27 individuals of African descent obtained from Dr M. R.
Hayden (University of British Columbia, Vancouver, Canada); (3) 94
Caucasians obtained from the Coriell Cell Repository (http://coriell.
umdnj.edu/); and (4) 94 Caucasian patients diagnosed with Gilbert
syndrome. For genetic diversity and molecular evolutionary studies,
we examined an additional 94 ethnically diverse unaffected humans,
who included African (African-American, Mbuti, Biaka), American
(Cheyenne, Mayan, Quechua, Karitiana), Asian (Indo-Pakistani,
Chinese, Japanese), European (Russian, Italian, Northern European,
Icelandic), Middle Eastern (Ashkenazi Jewish, Druze Arab) and
Oceanic people (Pacific and Melanesian). Ethnically diverse DNA
samples were obtained from the Coriell Cell Repository (http://
coriell.umdnj.edu/) and do not overlap with any of the Coriell ethnically
matched control subjects described above. Great ape tissues were
obtained from Dr E. Eichler (University of Washington, Seattle, USA).
DNAs (three chimpanzees, three gorillas, three orangutans) were
isolated from either lymphoblasts or fibroblasts using the Gentra
Puregene kit (Minneapolis, MN, USA). Macaque DNAs (two rhesus
macaques, two Japanese macaques) were obtained from Oregon
Regional Primate Research Center (Beaverton, OR, USA).
DNA amplification and sequencing
We sequenced NR2E1 using DNA amplicons generated from 20 poly-
merase chain reaction (PCR) assays that covered the coding region
(1146 bp), complete 50-a n d3 0-UTRs (1973 bp) and exon-flanking regions
includingconsensus splice sites (1719 bp). In addition, we sequenced six
evolutionarily conserved non-coding regions including proximal promoter
(1528 bp) as previously described (Abrahams et al. 2002). Human
genomic NR2E1 sequence AL078596 (http://www.ncbi.nlm.nih.gov/)
was used as the reference sequence. Polymerase chain reactions were
performed in a 96-well microtitre plate thermal cycler. Polymerase chain
reactions were prepared in a total volume of 20 ml using 10 ng of
genomic template and the following reagents from Invitrogen (Burling-
ton, Ontario,Canada): 1  buffer,1 mM MgSO4,0.2mMdNTPs,0.5mM
primer [each of forward and reverse (Table 2)] and 0.0125 units Pfx
polymerase. Thermal cycling was performed as follows: 30 cycles, 948C
for 2 min, annealing T (58–638C) for 30 seconds, 688C for 1 min.
Polymerase chain reaction products were purified using magnetic beads
from Agencourt Bioscience Corporation (Beverly, MA, USA) as per
manufacturer’s instructions. Non-human primate sequencing reactions
used 10–20 ng of DNA under similar conditions. Sequencing reactions
performed in 384-well plates were as follows: BD Ready Rxn Mix V3
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Patient ID Ethnicity Sex Brain abnormality MR Seizures Psychosis Stature Vision problems Other
CMS 3226 b m mic Yes Yes No Short u  
CMS 5041 b m mic Yes No Yes Normal u  
CMS 5811 b m mic Yes Yes Yes Short u  
CMS 5162 w m mic Yes Yes Yes Short u  
CMS 4775 w m mic Yes Yes No Short u  
CMS 5207 b m mic Yes Yes No Normal Yes  
CMS 5315 b m mic Yes Yes No Short u  
CMS 7456 u m mic Yes No Yes u u  
CMS 5538 b m mic Yes No Yes Normal u  
CMS 5838 b m mic Yes No Yes Normal u  
CMS 5151 w m mic Yes No Yes Normal u  
12856 u m mic Yes No Yes Normal u  
17763 w m mic Yes Yes Yes Normal u  
8348 b m mic Yes Yes Yes u u  
11362 w m mic Yes No Yes Normal u  
29494 w m mic Yes Yes No Short u  
LP95-042a2 w m mic msg Severe Yes u u No Early death
LP97-105 u f mic msg xax u u u u u  
LP98-038a1 w f mic msg Moderate No No u No  
LP98-052 w m mic msg pmg Severe Yes u u No Early death
LP98-095 w f mic msg Mild No No u No  
LP99-035 w m mic msg Severe u u u u Jejunal
LP99-0100a1 w-me f mic msg Severe Yes u u u  
LP99-156 w m mic msg bch Severe u u u u Early death
LR00-025 u m mic msg u Yes u u u  
LR00-144 w m mic msg Severe Yes u u u Early death
LR00-182a1 w-ash j f mic msg Severe Yes u Normal No  
LR00-188 w-me m mic msg u u u u u  
LR00-196 u m mic msg acc Severe u u u u Jejunal
LR00-204 u f mic msg Severe u u u u Jejunal
LR01-068 w f mic msg u u u u u  
LR01-099 u f mic msg bch xax acc Severe Yes u u Optic atrophy  
LR01-148 u f mic msg bch xax Severe Yes u u No  
LR01-171 w-me m mic msg Mild No No Normal No  
LR01-194 w m mic msg bch acc Severe Yes u u u  
LR01-224 w m mic msg xax Moderate No No Normal Yes  
LR01-265 w f mic msg Severe Yes u u No  
LR01-271 w f mic msg acc u Yes u u u  
LR01-314 u m mic msg u Yes u Normal No  
LR01-338 w f mic msg u No u u No  
LR01-356 w-me m mic msg bch u u u u u  
LR02-005 w f mic msg xax u u u u u  
LR02-016a3 w u mic msg bch u u u u u  
LR02-046 w f mic msg acc u No u u u  
LR02-080 u m mic msg u u u u u  
LR02-085 w f mic msg Mod-severe Yes u u Amblyopia  
LR02-112 u f mic msg xax u No u u u  
LR02-153 w-me f mic msg bch u u u u u  
LR02-154a1 w f mic msg xax u Yes No u Sclerocornea  
LR02-171 u m mic msg acc u u u u micr scl  
LR02-304 u m mic msg u No u u u  
LR02-421 w m mic msg dd u u u u  
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NR2E1-candidate-regulatory mutations(0.54 ml), 5  Reaction Buffer (0.43 ml), 5 mMP r i m e r( 0 . 2 6ml; Table 2), 0.2
mM1 8M V ddH20 (0.77 ml) and DNA (5–100 ng). Sequences were
visually inspected and scored by at least two individuals using either
Consed (Gordon et al. 1998) or Sequencher (GeneCodes, Ann Arbor, MI,
USA). Every human variant that was identified only once (i.e. singletons)
was confirmed by repeating the PCR and sequencing process. The CA-
repeat assay (D6S1594; GenBank Accession Z52880) was prepared in
a total volume of 15 ml using 10–50 ng of genomic template and the fol-
lowing reagents from Invitrogen: 1  buffer, 2.5 mM MgSO4,0 . 2 5m M
dNTPs and 0.04 units Pfx polymerase. Primers (0.5 mM) were fluo-
rescently labeled with FAM (ABI, Foster City, CA, USA). Post-PCR
products were diluted 1:30 with ddH2Oa n d1ml was combined with a
9.5 ml mix of formamide and Gene Scan
TM 400HD ROX as per
manufacturer’s instructions (ABI). Samples were denatured at 958Cf o r
5 min and placed on ice until loaded onto the ABI 3100 Genetic Analyzer
(ABI). Polymerase chain reaction fragments were analyzed using Gene
Mapper 3.0 (ABI).
Transcription factor binding site (TFBS) analyses
To predict whether genetic variants at NR2E1 (i.e. candidate muta-
tions, polymorphisms and human-specific nucleotides) alter experi-
mentally validated consensus-binding sequences for neural
transcription factors, we performed TFBS analyses using MatInspec-
tor (Quandt et al. 1995). We analyzed the minor and major alleles at
each variant site together with 50 bp of surrounding sequence using
Table 1: Continued
Patient ID Ethnicity Sex Brain abnormality MR Seizures Psychosis Stature Vision problems Other
LR03-059 u f mic msg xax dd Yes No u u  
LR03-184a1 u m mic msg bch Severe Yes No u u  
LR03-277 u m mic msg xax Severe u u u u  
gEMS594 u m mic Severe u u Short Micropthalmia  
Ethnicity: b, black; w, white; w-me, white-Middle Eastern; w-ash j, white Ashkenazi jewish; u, unknown.
Sex: f, female; m, male.
Brain abnormality: acc, agenesis of the corpus callosum; bch, brainstem-cerebellar hypoplasia; mic, microcephaly; msg, microcephaly with
simplified gyral pattern; pmg, polymicrogyria, xax, enlarged extra-axial space.
MR: MR, mental retardation; note that for some patients, MR was scored as being present (i.e. ’yes‘) whereas for other patients the severity of
MR was noted (i.e. mild, moderate, moderate-severe (Mod-severe), or severe); dd, developmental delay.
Vision problems: micr scl, micropthalmia and sclerocornea.
Other: jejunal, jejunal atresia; , no other phenotypes noted.
u, unknown.
Table 2: Polymerase chain reaction primers used to amplify NR2E1 sequences
Assay
Forward* Reverse
†
Name Sequence Name Sequence
CE11A oEMS1988 50-TACGCCTTAAATCCGAGGTC-30 oEMS1989 50-CGATCAAGCATGGTGTCAAG-30
CE12A oEMS1990 50-TGACACCGAGTCTGGAGAAA-30 oEMS2031 50-GTCGCCTCCATTATCTGCAC-30
CE13A oEMS1994 50-CAGCTCTGCTTGGGGGAAG-30 oEMS1995 50-AAAACGCTTTTCCCCCTCT-30
CE14A oEMS1998 50-TCCTTCTTGCCGTGAAATATAC-30 oEMS2032 50-GGAAAACTAGATTGCTGGGAAAT-30
50-UTRa oEMS2033 50-CCAGGGACGCCCTATTCC-30 oEMS2034 50-GAGGAAGAAGGAAGAACAGCA-30
50-UTRb oEMS2035 50-CCCACACTCTGCATGCCTAT-30 oEMS2036 50-GACAGGTGGGTGTCAGTCG-30
Exon1 oEMS2037 50-TGTGTCCATATCAAGCAGCA-30 oEMS2038 50-CTCCACGAAATGCTCCAACT-30
CE17B oEMS2011 50-GGAGAGCAGAGCGATGTCAC-30 oEMS2012 50-TCACGAGACAAGCTGGTTGA-30
CE19B oEMS2013 50-CCTCCCACAGCACAATCTC-30 oEMS2016 50-GTCCCAGACTCGTCTCAGGT-30
Exon2 oEMS1966 50-TTCGGTGCTAATCCCTTCAG-30 oEMS1967 50-AGAGGAAGGGAGAGGTCAGG-30
Exon3 oEMS1968 50-GGACTGGCCCTCTTGAAGTA-30 oEMS1969 50-TCCCAGCATCTGGAAAGAAG-30
Exon4 oEMS1970 50-CTCCCTCAGATTCCCTCTCC-30 oEMS2039 50-AACTGGGTGCGTCCCTCT-30
Exon5 oEMS1972 50-TACCCACCAATGTCAACTGC-30 oEMS1973 50-AACCCACAGGAAGAAGCAAG-30
Exon6 oEMS1974 50-TGGGAAAATAAGGGAAAGCTAGA-30 oEMS1975 50-ATTTAAATAACAATGCAAGCAGTCA-30
Exon7 oEMS1976 50-CTTTCATACAATATAGCCGGTTTACA-30 oEMS1977 50-AACATGCAGGTTCCCATAGC-30
Exon8 oEMS1978 50-GATTACAGACACATGCCACCAT-30 oEMS1979 50-CACCCACCCTGAGAGATAGG-30
Exon9 oEMS2040 50-TTCAAGTGTAAGACGTTAGTTTCCA-30 oEMS2041 50-CTGTGGCAACCCCCAGTT-30
30-UTRa oEMS2042 50-AAAGCATTCCAGTAGCTATGACC-30 oEMS2043 50-GTTGCCTGGCCTATGGTATT-30
30-UTRb oEMS2044 50-CATTATTAAGTGGCCTTCAGAACT-30 oEMS2045 50-CAGTTTTCGGAAAGGCATTG-30
30-UTRc oEMS2046 50-CCAGACAGGAAACGAATATGG-30 oEMS2047 50-CCTTGTTTCTGGTGGGTGAG-30
*50-TGTAAAACGACGGCCAGT-30 sequence (-21M13F) was added to the 50 end of each forward primer to facilitate sequencing.
†50-CAGGAAACAGCTATGAC-30 sequence (M13R) was added to the 50 end of each reverse primer to facilitate sequencing.
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on transcription factors with brain-relevant roles that include cortical
patterning, neural cell proliferation and differentiation, neuronal apo-
ptosis, neuronal survival and synaptic plasticity.
Evolutionary, nucleotide diversity and genetic
differentiation analyses
The following standard measures of genetic diversity were calculated
using DnaSP version 3.0 (Rozas & Rozas 1999): S (the number of
segregating sites); and yW and p (nucleotide diversity). The following
statistical tests of selection were performed using DnaSP version 3.0
(Rozas & Rozas 1999): Tajima’s D-test (which compares the number of
nucleotide polymorphisms (yW) with the mean pairwise difference
between sequences (p); Fu and Li’s D
* (which compares the number
of derived nucleotide variants observed only once in a sample with the
total number of derived nucleotide variants); Fu and Li’s F
* (which
compares the number of derived nucleotide variants observed only once
in a sample with the mean pairwise differences between sequences)
and Fay and Wu’s H (which compares the number of derived nucleotide
variants observed only once in a sample with the mean pairwise
differences between sequences). Non-human primate outgroups were
used to infer the ancestral and derived states of human variants. The P
values for Tajima’s D and Fay and Wu’s H were estimated from 10 000
coalescent simulations of an infinite site locus that conditioned on the
sample size. Human and non-human primate sequence data were
aligned usingMEGA version 3.0 (Kumaret al.2004c) andhuman-specific
variants wereidentifiedvisually andconfirmed by at least two individuals.
Haplotype and linkage disequilibrium reconstruction
We reconstructed haplotypes and estimated their frequencies by
implementing PHASE (V. 2.0). We calculated haplotype diversity for
each population as 2n(1 Sxi
2)/(2n 1), where xi is the frequency of
haplotype i and n is the sample number. Pairwise linkage disequilib-
rium (LD) between each common SNP was computed as |D’| and r
2
using DnaSP version 3.0 (Rozas & Rozas 1999). We did not analyze
the indels because gaps are excluded from the LD analyses (Rozas &
Rozas 1999). Significance of LD was tested using Fisher’s exact test
after Bonferroni adjustment for multiple tests.
Results
Candidate NR2E1 mutations identified in patients
with cortical abnormalities
In total, we generated approximately 368 220 bp of NR2E1
sequence data. We did not detect any synonymous or non-
synonymouscodingvariants. Nineout ofthe 56patients(16%)
were homozygous across all sites sequenced, which spanned
25.5 kb. We identified 11 patients harboring 15 novel non-
coding variants (i.e. variants that have not been previously
reported (http://www.ncbi.nlm.nih.gov/projects/SNP/; Build
124) (Table 3). Each of these variants (herein referred to as
‘patient variants’) was present in the heterozygote state.
Thirty-three percent of the patient variants resided within the
proximal promoter, 33% within a UTR and 33% within intronic
sequence. Transitions and transversions accounted for 47%
and 53% of all variants, respectively.
Four patients harbored multiple patient variants, including
patients LR00-44, LR03-184a1, LR00-204 and LR03-277, in
whom we identified three, two, two and two patient variants,
Table 3: Characterization of 15 NR2E1 patient variants in families and control subjects
Patient ID* Location
†
Genotype
§
Frequency of patient variant in
control chromosomes
¶ Nucleotide variant
‡ Patient Unaffected father Unaffected mother Sibling
LR00-144 CE11A g.-2945A>G A/G A/A A/G n/a 0/330 (0%)
LR00-144 PPR g.-1767G>T G/T G/G G/T n/a 0/518 (0%)
LR00-144 30-UTR g.21502TG>C T/C T/C T/T n/a 0/344 (%)
LR03-184a1 PPR g.-1431C>A C/A C/C C/A C/C 6/528 (1.1%)
LR03-184a1 Intron 1 g.151T>A T/A T/T T/A T/T 6/350 (1.7%)
LR00-204 PPR g.-1453C>G C/G C/C C/G n/a 1/528 (0.2%)
LR00-204 Intron 5 g.11559C>T C/T C/T C/C n/a 2/550 (0.4%)
LR03-277 30-UTR g.21762C>A C/A C/A C/C n/a 1/352 (0.3%)
LR03-277 30-UTR g.21796G>A G/A G/G G/A n/a 1/352 (0.3%)
LR02-304 CE12A g.-1726C>A C/A C/A C/C n/a 0/528 (0%)
LP98-052 PPR g.-1453C>G C/G C/G C/C n/a 1/528 (0.2%)
CMS5151 50-UTR g.-555C>T C/T n/a n/a n/a 2/540 (0.4%)
8348 Intron 3 g.8213T>C T/C n/a n/a n/a 0/146 (0%)
12856 XS Intron 7 g.14617A>C A/C n/a n/a n/a 1/558 (0.2%)
LR01-194 Intron 7 g.14718C>T C/T C/C C/T n/a 1/558(0%)
LR01-148 30-UTR g.20765C>A C/A n/a n/a n/a 0/362 (0%)
*Note that patients LP98-052 and LR00-204 both harboured identical variants (i.e. g.-1453C>G). Thus, a total of 15 novel variants were identified.
†PPR, proximal promoter region (defined as a 2.0-kb region upstream of the initiator Met codon); CE, evolutionary conserved element within PPR
(as described in Abrahams et al. 2002); UTR, untranslated region.
‡g, genomic; numbering based on Antonarakis and the Nomenclature Working Group [1998], where A of the initiator Met codon in exon 1 is
denoted nucleotide þ1. Human genomic NR2E1 sequence: NCBI AL078596.
§Sibling of LR03-184a1 is affected with microcephaly with simplified gyral pattern.
¶numbers represent the total number of successfully sequenced chromosomes and not the total number of chromosomes screened.
n/a, not available.
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NR2E1-candidate-regulatory mutationsrespectively. Patients LR00-204 and LP98-052 both harbored
the g.-1453C>G substitution.
We amplified and sequenced the regions corresponding to
the 15 novel patient variants in 15 additional family members
(Table 3). Fourteen parents were available for typing for 12 of
the 15 novel patient variants, including both parents for the
two unrelated patients having the identical g.-1453C>G
patient variant. In all 12 cases, at least one unaffected parent
harbored the patient variant, indicating that none of these
variants were de novo. For four patient variants, parents were
unavailable for typing; therefore, we cannot exclude the
possibility that these variants are de novo. An affected sibling
was studied for both patient variants identified in patient
LR03-184a1; neither of the two variants was identified in the
sibling, suggesting that the two patient variants do not predict
the cortical phenotypes in these siblings.
We amplified and sequenced the regions corresponding to
the 15 novel patient variants in ethnically matched controls of
African (274 chromosomes) and European (376 chromo-
somes) descent. If the ethnicity of the patient was unknown,
the patient variants were genotyped in chromosomes of
African and European descent (650 chromosomes). None of
the control subjects were reported to have cortical malforma-
tions. Of the 15 novel variants identified in the patients, seven
(g.-2945A>G, g.-1767G>T, g.-1726C>A, g.8213T>C,
g.14718C>T, g.20765C>A and g.21502T>C) were not de-
tected in any control subject (Table 3). These seven patient
variants will now be referred to as ‘candidate mutations’.
Three of the seven candidate mutations (g.-2945A>G,
g.-1767G>T and g.21502T>C) were identified in patient
LR00-144: two of these (g.-2945A>G and -1767G>T) were
maternal and one (g.21502T>C) was paternal. Consequently,
patient LR00-144 is a compound heterozygote for NR2E1
mutations. Importantly, both g.-2945A>G and g.-1767G>T
reside within the proximal promoter (PPR) and g.21502T>C
resides within the 30-UTR, which makes each of these
variants reasonable candidates for putatively regulatory hypo-
morphic mutations. The four remaining candidate mutations
were identifiedindividually in unrelated patients. Two of these
reside within putative regulatory regions (g.-1726C>Ai n
a 100-bp element in the PPR that is conserved between
mouse and human; and g. 20765C>A that resides in the 30-
UTR); the remaining two candidate mutations were identified
in intronic regions outside the consensus splice site.
Two additional patients were compound heterozygotes
for patient variants of NR2E1. Patient LR00-204 harbored
g.-1453C>G (maternal) and g.11559C>T (paternal), each pre-
sent in the general population at 0.2% and 0.4%, respec-
tively. Patient LR03-277 harbored g.21762C>A (paternal) and
g.21796G>A (maternal), both present in the general popula-
tion at 0.3%. We did not identify a single control subject
bearing either g.-1453C>G / g.11559C>T or g.21762C>A/
g.21796G>A allelic pairs. We therefore consider these var-
iants as candidates for rare functional polymorphisms.
Predicted alterations of consensus transcription
factor binding sites by NR2E1 candidate mutations
To predict the impact of the seven candidate mutations on
transcription factor binding, we performed in silico analyses
on experimentally-validated consensus sequences for TFBS.
We restricted our analyses to transcription factors expressed
in the brain. Of the seven candidate mutations, four (g.-
1767G>T, g.-1726C>A, g.8213T>C, g.14718C>T) were pre-
dicted to create or abolish binding of transcription factors
known to have roles in neuronal proliferation and survival,
cortical patterning, neuronal differentiation and synaptic plas-
ticity (Table 4). Of the four functional polymorphisms, one (g.-
1453C>G) was predicted to create binding of two neural
transcription factors (Table 4).
To determine whether functional constraint may exist at
the sites corresponding to the seven candidate mutations, we
determined the orthologous major allele at each of the sites in
chimpanzee, gorilla, orangutan, macaque, mouse and Fugu.
Notably, in two instances (g.-1726C>A and g.8213T>C), the
major human nucleotide was conserved to Fugu (Table 4).
The absence of nucleotide variability at these two non-coding
sites between human and Fugu, which are separated by 900
million years (Kumar & Hedges 1998), suggests strong
functional constraint and supports the proposal that these
sites may represent putative regulatory regions.
To determine whether the NR2E1 candidate mutations
mayreside within cis-a c ti n gUT Rmo t i fsth ata rek n o w ntob e
critical for many aspects of gene expression and regulation
(Mignone et al. 2002), we searched for the presence of ex-
perimentally validated functional motifs in the 50-a n d3 0-UTR
of NR2E1 using UTRscan (Mignone et al. 2005). We identi-
fied three motifs in the 50-UTR (15-LOX-DICE, IRES, Brd-
B o x )a n dt w oi nt h e3 0-UTR (IRES, Brd-Box); however, none
of these motifs included a candidate mutation. To determine
whether any of the candidate mutations may alter 30-UTR
binding for microRNAs (miRNA), which are known to regu-
late genes (Bartel 2004), we aligned the 30-UTR of NR2E1
against known miRNA motifs (Xie et al. 2005). We detected
two motifs; however, neither included a candidate mutation.
Strong purifying selection and low nucleotide
diversity at NR2E1 in ethnically diverse humans
Genetic diversity and molecular evolutionary studies of neural
genes in humans and non-human primates represent power-
ful tools for understanding cortical development (Enard &
Paabo 2004; Gilbert et al. 2005). We therefore sought to gain
additional insight into the extent and patterns of genetic
variation at NR2E1 by systematically resequencing the same
coding and non-coding regions as described above in 94
unaffected, ethnically diverse humans representing Africa,
the Americas, Asia, Europe, the Middle East and Oceania;
none of these humans was studied as part of the data set
used as controls in our previous analyses. In addition, we
studied NR2E1 in chimpanzee, gorilla, orangutan, Japanese
macaque and rhesus macaque. The human sample size
chosen was sufficient to detect alleles with minor allele
frequencies of 10% or greater with 90% power.
We did not detect a single non-synonymous or synony-
mous change in the coding region of any human sample. We
also did not detect a single non-synonymous change in any
non-human primate sample (2–3 individuals from five spe-
cies). The complete lack of synonymous variation among
humans and the complete absence of non-synonymous
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NR2E1-candidate-regulatory mutationsvariation between humans and non-human primates suggests
that NR2E1 has experienced strong functional constraint (i.e.
purifying selection).
In this ethnically diverse sample, we observed a total of 25
non-coding variants (Fig. 1a; variants 1–25). Twenty-three of
the 95 subjects (24%) were homozygous across all
sequenced sites. Twenty of the 25 variants were novel
(http://www.ncbi.nlm.nih.gov/projects/SNP/; dbSNP Build
124) (Fig. 1b). None of the seven candidate mutations iden-
tified in patients were detected in this unaffected ethnically
diverse human panel. Consequently, if we include control
subjects of mixed ethnic origin into our analyses of candidate
mutations, the total number of unaffected chromosomes not
harboring candidate mutations is as follows: g.-2945A>G
(518 chromosomes), g.-1767G>T (706 chromosomes), g.-
1726C>A (716 chromosomes), g.8213T>C( 3 3 4c h r o m o -
somes), g.14718C>T (746 chromosomes), g.20765C>A
(550 chromosomes) and g.21502T>C (532 chromosomes).
We determined the frequencies of all 25 variants in each
ethnic group. Only six of the 25 variants (numbers 2, 7, 8, 14,
17 and 21) were common (i.e. minor allele frequency (MAF)
 5%) (Fig. 1c). For each human variant, we also inferred the
ancestral and derived states by comparing it to the orthologous
non-humanprimatesequence (Fig. 1d). Interestingly, chimpan-
zee, gorilla and orangutan were all polymorphic for the same
G>A transition (variant 8) observed in humans. This is the first
report of a human polymorphic site that is also polymorphic for
the same alleles across these three great apes.
Figure 1: A few common and many rare NR2E1 variants detected in human populations representative for global diversity.
(a) Functional and putatively functional regions of NR2E1 were resequenced, including coding (dark purple boxes), 50- and 30-untranslated
(light purpleboxes), and human non-coding regions that are conserved (Abrahamset al. 2002) in mouse (CE-A; red boxes)and mouse and
Fugu (CE-B; yellow boxes). (b) A total of 26 variants was identified (variants 1–25 and CA-repeat, see Fig. 2). The nucleotide in the first
position represents the human major (i.e. consensus) allele. Numbering based on Antonarakis and the Nomenclature Working Group
(Antonarakis 1998), where A of the initiator Met codon in exon 1 is denoted nucleotide þ1. Human genomic NR2E1 sequence: AL078596
(http://www.ncbi.nlm.nih.gov/). Variants catalogued in dbSNP (‘Y’) are distinguished from those that are newly discovered here (‘N’). The
DNA context of each variant is shown. (c) The number of chromosomes surveyed (n) and minor allele frequencies for each variable site
are indicated for 18 world populations. (d) The corresponding chimpanzee, gorilla, orangutan, rhesus macaque, and Japanese macaque
alleles are indicated. ‘x’ indicates that no sequence was obtained due to failed PCR or sequencing reaction. ‘ ’ indicates that no
corresponding nucleotide was present at that position in the non-human primate.
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Kumar et al.We estimated the levels of human nucleotide diversity by
computing yW, which is based on the proportion of segregat-
ing sites (S) in a population and p, which is based on the
average number of nucleotide differences per site between
two sequences randomly drawn from the population (Hartl
1997) (Table 5). The total human estimates for yW (5.7   10
 4
  0.17   10
 4) and p (2.6   10
 4   0. 20   10
 4) for NR2E1
fall at the lower 20% and 30% of previous studies, respec-
tively (Przeworski et al. 2000).
Evidence of non-neutral evolution at NR2E1
Genes that have been implicated in severe cortical malforma-
tions, including ASPM (Evans et al. 2004b) and Microcephalin
(Evans et al. 2004a), show robust molecular signatures of
positive Darwinian selection; consequently, the identification
of signatures of selection in candidate neural genes such as
NR2E1 may strengthen their proposed role in human cortical
disorders. To elucidate the human molecular evolution of
NR2E1, we first used the nucleotide diversity measures yW
and p to calculate Tajima’s D (Tajima 1989) (Table 5). Positive
and negative values of this test correspond to departures from
the neutral expectations of molecular evolution. We obtained
a negative value for Tajima’s D in the ethnically diverse
population, which is consistent with another report that ob-
tained a negative Tajima’s D at NR2E1 (Stephens et al. 2001).
To further evaluate the role of natural selection at NR2E1,
we used the ancestral and derived states of each variant from
the ethnically diverse population to perform three additional
tests of molecular neutrality: Fu and Li’s D* (Fu & Li 1993), Fu
and Li’s F* (Fu & Li 1993) and Fay and Wu’s H (Fay & Wu
2000). We obtained statistically significant negative values for
Fu and Li’s D* and F* (Table 6), which may indicate genetic
hitchhiking or background selection. However, based on
these tests alone, we cannot exclude the possibility that
Table 5: Human nucleotide diversity and Tajima’s D at NR2E1
Population nS yW ( SD) p ( SD) ZS Tajima’s D
Africa 36 12 0.00045 0.00024 8  1.45
(0.00018) (0.00004)
Americas 28 6 0.00024 0.00029 0 0.61
(0.00012) (0.00005)
Asia 18 6 0.00027 0.00027 0  0.36
(0.00014) (0.00006)
Europe (C) 24 3 0.00013 0.00017 1 0.83
(0.00008) (0.00002)
Europe (N) 34 7 0.00027 0.00027 1  0.04
(0.00013) (0.00004)
Middle-East 26 7 0.00029 0.00022 5  0.75
(0.00014) (0.00003)
Oceania 22 5 0.00022 0.00020 0  0.18
(0.00004) (0.00004)
Total human 188 21 0.00057 0.00026 11  1.50
(0.00017) (0.00002)
n, number of alleles; ZS, number of singleton mutations; S, number of segregating sites.
Table 6: Neutrality tests using chimpanzee as outgroup
Population Fu and Li’s D
* Fu and Li’s F
* Fay and Wu’s H
Africa  2.77
†  2.79
‡ 0.89
Americas 1.27 1.26 1.14
Asia 1.33 1.11 0.86
Europe (C)  0.24 0.07 0.31
Europe (N) 1.24 1.13 0.77
Middle East  1.97  1.81 0.69
Oceania 1.22 0.96 0.19
Total human  3.08
†  2.63
‡ 0.98
†P < 0.02.
‡P < 0.05.
Table 7: NR2E1 sites that are fixed among all humans but differ
in non-human species
Region
Location*
(bp) Humans
†
Great
apes
‡
Old world
monkeys
§ Mouse
¶
CE11A  2994 G A A A
50-UTR  542 T C C C
50-UTR  498 A T T T
Exon 4
††
9843 A T T T
30-UTR 21090 C T T na
*Numbering adopted from Antonarakis et al. (1998), where A of the
initiatorMetcodoninexon1isdenotednucleotideþ1.Humangenomic
NR2E1 sequence: NCBI AL078596.
†includesallhumansexamined(African,Asia,Americas,Europe,Middle
East, Oceania).
‡includes all chimpanzees, gorillas, orangutans examined.
§includes all rhesus and Japanese macaques examined.
¶na, orthologous region does not align with human sequence.
††CCA_(Pro) to CCT_(Pro).
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Kumar et al.demographic factors such as population bottlenecks may also
explain deviations from neutrality observed at NR2E1 (Fu
1997; Kreitman 2000).
Human-specific NR2E1 sites identified
Insight into the evolution of human-specific traits, such as
enlarged cerebral cortex, may be gained by the identification of
human-specific sites (i.e. nucleotides that are fixed among all
humans but absent from non-human species) (Enard & Paabo
2004). Toidentifysuchsites,wealigned 6137bpofhuman and
non-human primate coding and non-coding sequences. We
identified26 human-specific(divergent) sites (data not shown).
Of these 26, five resided within functional (i.e. exons) or
putatively functional (i.e. evolutionarily conserved non-coding)
regions of NR2E1: one synonymous coding variant and four
putative regulatory variants (Table 7). We extended our analy-
sis to mouse and determined that four divergent sites still
remained (the 30-UTRs between human and mouse NR2E1
could not be aligned) (Table 7). To determine whether these
four variants may disrupt or create TFBS, we performed in
silicoTFBSanalyses. We didnotdetectanyalterationsofTFBS
for transcription factors expressed in the brain.
NR2E1 haplotype and LD structure provide effective
tools for disease-mapping studies
To inform future association and linkage-based studies of
NR2E1 in disorders of brain and behavior, we elucidated
haplotype structure and LD using a subset of the 21 novel
variants identified in our analyses of ethnically diverse and
unaffected humans. To characterize the haplotype structure
of human NR2E1, we inferred haplotypes using bi-allelic
variants whose MAFs were 5% or greater. Genotypes of all
markers were in Hardy–Weinberg equilibrium (data not
shown). For each individual, we inferred haplotypes (Fig. 2a)
and estimated the population haplotype frequencies for all
seven human populations (Fig. 2b). We also typed a 12-allele
CA-repeat in the 30-UTR (dinucleotide repeat range 17–31;
data not shown). We then re-constructed haplotypes using
the CA-repeat data and the five most common haplotypes
(Fig. 2c). Our characterization of haplotype structure in
NR2E1 identified five haplotypes and CA-repeat alleles that
would be useful for disease-mapping studies.
To empirically estimate the degree of non-random associa-
tion between NR2E1 variants, we calculated LD using two
statistics: Lewontin’s coefficient |D’| and Pearson’s correlation
r
2(Ardlieetal.2002).WeusedallthevariantswithMAFsequal
to or greater than 5% except indel variant 17 for technical
reasons (see Materials and methods). Despite our markers
being only a few kilobases apart, in most cases we observed
weak LD in this region (data not shown); however, we note
that small sample sizes may underestimate the extent of
significant LD. The only substantial LD in NR2E1 was between
variants 2 and 7 (|D’| ¼ 0.894; r
2 ¼ 0.880; Fisher P < 0.001,
significant using the conservative Bonferroni correction). We
also examined the relationship between LD and distance using
both|D’|a n dr
2, which indicated a general decreaseinthe level
of LD with increasing distance (data not shown).
Discussion
The present study represents the first genetic report of
NR2E1 in clinical samples. In addition, it provides the most
comprehensive evolutionary study of NR2E1 reported to
date. Our studies of NR2E1 are noteworthy in several
respects. First, we used a direct resequencing approach,
which is the most reliable, complete and impartial means of
mutation and polymorphism discovery; however, one limita-
tion of using this approach alone is its inability to distinguish
between homozygosity across loci vs. large deletions. Sec-
ond, our experiments were designed to identify candidate
mutations and polymorphisms in both coding and key non-
coding regions, such as evolutionarily conserved sequences
that may harbor functionally important and disease-causing
variants (Drake et al. 2006). Third, we studied a diverse
collection of human genomic DNAs representing the world’s
major continental populations as a means to thoroughly
assess the natural genetic variation at this locus.
Our candidate mutation screen demonstrated that protein-
coding mutations in NR2E1 do not contribute to cortical and
behavioral abnormalities in the patients examined here. In
addition, we detected individuals homozygous across the
NR2E1 locus, but given the overall lack of variability at
the locus and the fact that these cases were not enriched in
the patient sample, this data does not argue for the presence
of large deletions. We did identify and characterize seven
candidate non-coding mutations and four candidate functional
polymorphisms. Of particular interest is patient LR00-144,
who is a compound heterozygote for candidate NR2E1
mutations, which is consistent with the recessive inheritance
of the cortical phenotype in Nr2e1
 /  mice. Strikingly, patient
LR00-144 harbored three of the seven candidate mutations.
The chances of observing threecandidate mutations in a single
Figure 2: Five common SNP-based NR2E1 haplotypes account for the majority of chromosomes examined for global diversity.
(a) The SNP-based haplotypes for both chromosomes of every individual are illustrated. Each row represents one chromosome. Each
column represents one variable site, the number of which is indicated above each column (see Fig. 1b). Black boxes indicate the major
allele; white boxes represent the minor allele. Coriell Cell Repositories ID codes are indicated. ‘SNP’ refers to single nucleotide
polymorphism (i.e. single nucleotide substitutions with minor allele frequencies  1%). ‘Prob’ is the probability of haplotype assignment,
where 1.00 ¼ 100% probable (i.e. individual is either homozygous at all sites or a heterozyote for only one site). MB, Mbuti; BK, Biaka;
AA, African-American; CH, Cheyenne; MA, Mayan;QU, Quechua;KA, Karitiana; IP, Indo-Pakistani; CN, Chinese; JA, Japanese; IT, Italian;
RU, Russian; NE, Northern European; IC, Icelandic; AJ, Ashkenazi Jewish; DA, Druze Arab; PA, Pacific Islanders; ME, Melanesian.
(b) Estimated population haplotype frequencies of the 13 most frequent SNP-based NR2E1 haplotypes. ‘ ’ indicates that the haplotype
is absent from the population. ‘1’ and ‘0’ represent present and absence of TC indel, respectively. (c) The frequency (y-axis) of the
CA-repeat allele (x-axis) with the five most common NR2E1 haplotypes (z-axis) is plotted for the global diversity population.
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NR2E1-candidate-regulatory mutationspatient are extremely rare [(7 candidate mutations/56 pa-
tients)
3 ¼ 1.9   10
 3]. The g.-1767G>T candidate mutation
identified in this patient is predicted to create two transcrip-
tion factor binding sites (TFBS). One of these is for the zinc
finger protein insulinoma-associated 1 (IA-1), which is present
in fetal brain tissue and functions as a transcriptional repres-
sor during neuronal development (Breslin et al. 2002). IA-1
binding sites have been identified in the 50-flanking regions of
several genes including Pax6 and NeuroD/b2 (Breslin et al.
2002). The g.-1767G>T substitution is also predicted to
create a neural-restrictive-silencer element (NRSE). NRSE
motifs are known to bind the neural-restrictive silencer factor
(NRSF) that functions as a transcriptional repressor of multi-
ple neuronal genes such as NR2B, which contains five NRSE
motifs in its 50-flanking region (Qiang et al. 2005). The highest
expression of NRSF is observed in the mouse embryonic
cortex at E14, but is also detected in the adult mouse brain as
well as in cultured cortical neurons (Qiang et al. 2005). Taken
together, the creation of at least two transcriptional repressor
binding sites in the proximal promoter of NR2E1 in patient
LR00-144 supports the proposal that the g.-1767G>T candi-
date mutation could contribute to the cortical phenotype and
severe mental retardation observed in this patient.
Patients LR00-204 and LR03-277 also represent compound
heterozygotes for patient variants of NR2E1. Interestingly,
LR00-204, who had microcephaly, was also diagnosed with
optic nerve hypoplasia, a phenotype observed in Nr2e1
 / 
mice (Young et al. 2002; Yu et al. 2000). The specific pair of
candidate functional polymorphisms observed in each patient
was absent in all controls examined; thus, these particular
combinations of alleles were specific to cortical disorders.
Each of these variants may act through a hypomorphic
mechanism that involves reduced levels of NR2E1 transcrip-
tion. Such a mechanism is supported by the demonstration
that Nr2e1
þ/  mice show altered neurogenesis early during
cortical development (Roy et al. 2004), which indicates
dosage sensitivity for Nr2e1.
Patients 8348 and LR01-148 harbored candidate mutations
g.8213T>C and g.20765C>A, respectively. Parents of both
these patients were unavailable to study; consequently, we
cannot exclude the possibility that both these variants may
represent de novo mutations. The candidate mutation
g.8213T>C identified in intron 3 in patient 8348 is predicted
to abolish a binding site for OCT1, a regulator of neuronal
differentiation and is also predicted to create binding sites for
BRN5, another regulator of neuronal differentiation and
PAX6, a regulator of neuronal proliferation and fate. The major
allele T at this site is conserved between human and Fugu,
which strengthens the proposal that a nucleotide substitution
at this site may be pathogenic.
Finally, the two candidate mutations g.-1726C>Aa n d
g.14718C>T identified in patients LR02-304 and LR01-194,
respectively, may also underlie cortical disorders. However,
as each was also present in a parent, we propose a multigenic
mechanism underlying the cortical phenotypes in each case.
Such a proposal receives support from mice that are double
heterozygotes for mutations at Nr2e1 and Pax6,w h i c h
interact genetically to alter normal forebrain development
(Stenman et al. 2003). Both candidate mutations are pre-
dicted to alter neural TFBS and one of these (g.-1726C>A)
resides in the promoter region, which together strengthens
their candidacy for disease.
Our genetic diversity and evolutionary analyses of NR2E1 in
ethnically diverse humans and non-human primates will
inform future NR2E1 studies of human brain–behavior dis-
orders. Our data indicate strong evolutionary constraint (i.e.
purifying selection) in the coding region of NR2E1 that is
higher in comparison to many other genes examined for
genetic diversity (Cargill et al. 1999; Dorus et al. 2004;
Freudenberg-Hua et al. 2003) (http://genebank.nibio.go.jp/
gbank/qfbase/index.html). Studying additional non-human pri-
mates would serve to further strengthen this conclusion. The
implication of strong functional constraint is that any future
identification of an NR2E1 coding variant in a patient with
a brain–behaviour phenotype is likely to be related to the
disorder. Importantly, the striking absence of synonymous
changes, which are typically considered to be selectively
neutral (Enard & Paabo 2004), may suggest a functional
constraint that operates at the RNA level to maintain its
secondary structure or stability, as described for other genes
(Capon et al. 2004; Chamary & Hurst 2005; Duan et al. 2003).
We provide evidence of adaptive evolution at NR2E1 that
may act on regulatory sites, which constitute an important
class of non-coding sequences that are potential targets of
Darwinian selection (Wray et al. 2003). We observed an
excess of rare, derived NR2E1 variants, as indicated by the
significantly negative Fu and Li’s D* and F* values, which
could be evidence of a ‘selective sweep’ (i.e. the rare variants
have ‘hitch-hiked’ along with a variant on which positive
selection has occurred) (Fay & Wu 2000). In this regard, it is
conceivable that one or more of the human-specific NR2E1
sites identified in the present study may have been fixed by
positive selection in a manner similar to that proposed for
ASPM, which is mutated in some patients with microcephaly
(Bond et al. 2003; Kumar et al. 2004; Woods et al. 2005).
The knowledge of the genetic architecture of NR2E1
generated in this study in ethnically diverse humans and
non-human primates provides additional tools for future
disease-mapping studies of brain–behavior disorders. Our
results expand those of one other study that examined
normal genetic architecture at NR2E1 (Stephens et al.
2001); however, our analyses employed over twice as much
sequence data (including evolutionarily conserved regions not
previously examined) from a more diverse set of humans and
non-human primate species. The identification and character-
ization of common SNPs, microsatellites, and haplotypes in
multiple ethnic groups will benefit future association analyses
of brain–behavior disorders by helping to reduce or eliminate
false-positive and negative associations that can arise as
a result of population stratification, which is a well established
confound in human disease-mapping efforts (Freedman et al.
2004; Kang et al. 1999). We also provide the first example of
a human polymorphic site that is also polymorphic for the
same alleles in chimpanzee, gorilla and orangutan. Therefore,
we strongly recommend that multiple non-human primate
species be used to robustly infer ancestral states of human
polymorphisms.
In conclusion, our analysis of human NR2E1 has identified
candidate regulatory mutations and rare putative functional
polymorphisms. Future work will involve testing these alleles
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Kumar et al.for abnormal function using whole-animal assessment as
proposed by Abrahams et al. (2005). In this study, we
selected patients enriched for features resembling Nr2e1
 / 
mice in addition to microcephaly (e.g. four patients with
agenesis of the corpus callosum, one patient with optic
atrophy). Future research may benefit by focusing on other
region-specific malformations present in the Nr2e1
 /  mice,
such as preferential reduction of superficial cortical layers II
and III, in an effort to enhance detection of NR2E1 mutations.
Our genetic diversity and evolutionary analyses provide the
foundation to facilitate future examination of the role of
NR2E1 in additional human disorders of brain and behavior.
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